Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Nuevo enfoque científico para el tratamiento de la diarrea neonatal del ternero

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIE20160411001
Publicado:
29/04/2016
Caducidad:
29/04/2017
Resumen:
Una empresa irlandesa especializada en desarrollar tratamientos gastrointestinales de primera clase para enfermedades de animales ha desarrollado un nuevo tratamiento de la diarrea neonatal del ternero. Este tratamiento se ha formulado para incorporar un nuevo enfoque científico a la bioquímica intestinal y sanguínea y se caracteriza por la recuperación total y rápida y los protocolos de baja dosis. El producto, lanzado al mercado irlandés en 2015, ha sido analizado independientemente y utilizado en más de 22.000 terneros, con una respuesta excelente por parte de granjeros y veterinarios. La empresa busca socios con el fin de establecer acuerdos de licencia, fabricación y distribución.

Details

Tittle:
New scientific approach to neonatal calf diarrhoea treatment.
Summary:
An Irish based research company focused on developing best in class gastrointestinal treatments for production animal diseases has developed a new to market treatment for neonatal calf diarrhoea. The treatment is formulated to incorporate a novel scientific approach to intestinal and blood biochemistry. Its characterised by full, rapid recovery and low-dose protocols. It is applicable to a sizeable worldwide market and available via a licensing, manufacturing, commercial distribution agreement.
Description:
An Irish based research company which specialises in gastrointestinal treatments for production animal diseases has developed this product for neonatal calf diarrhoea which is the most common cause of morbidity and mortality in calves worldwide. There is scientific uncertainty regarding the optimal treatment for this disease. Accordingly, a large number of products are commercially available, differentiated by composition and administration protocols.

Following advanced scientific understanding of the intestinal and blood patho-biochemistry of this disease, the Irish research company has developed a new formulation to treat affected animals. Built upon novel scientific reasoning and sound peer-reviewed research data, the development of this treatment represents a new class of diarrhoea treatment.

The scientific attributes of the product formulation facilitate corrective action against the key components of the disease simultaneously, thereby facilitating rapid recovery from a low dose rate. In fact, the treatment has the quickest recovery time and the lowest dose rate available on the market.

Launched in Ireland in 2015, the product has been independently assessed and used commercially in over 22,000 calves. Feedback from veterinarians and farmers has been excellent. Demand has grown from 13,000 treatments (2015) to 150,000 (2016) in Ireland.

Marketed on the basis of 24 hours to recovery and on the basis of a two dose regime, irrespective of the disease severity, the product has found favour for its simplicity and efficacy. The product has worldwide application, to serve a significant market that is continually expanding on all continents.

Suitable licensing agreements are preferable on a continental or worldwide basis (excluding Europe) to include manufacturing and commercial distribution of the powder-based formula. Within Europe, suitable commercial distribution agreements are required on a continental or country-by-country basis to maximise product sales. Technical veterinary assistance and or/training is available.
Advantages and Innovations:
Advantages:
(1) Rapid recovery (24 hours, certified);
(2) Low dose protocol (two dose, certified, regardless of severity); (3) Enhanced buffering capacity;
(4) Maximum efficacy;
(5) Suitable to organic farming;
(6) Classed as a non-medicine;
(7) Treated calves regain lost production weight (certified);
(8) Corrects acidosis (certified);
(9) Corrects dehydration (certified)

Scientific innovation:
(a) A novel scientific approach to strong ion difference in an oral rehydration and buffering solution (ORBS);
(b) A novel scientific approach to alkalising agent in an ORBS
(c) Added tocopherol in an ORBS
Stage of Development:
Already on the market
IPs:
Patent(s) applied for but not yet granted,Trade Marks
CommeR Statunts Regarding IPR Status:
UK Patent on file. Within the year, patent filing action in the remainder of the EU, USA, Argentina, Brazil, India and Saudi Arabia, claiming priority form this UK Patent Application.

Partner sought

Type and Role of Partner Sought:
Animal health, animal nutrition or pharmaceutical companies are required in order to manufacture and commercially distribute the powder-based formula.

Optionally, veterinary distribution companies to facilitate distribution within Europe.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
Croatian
English
German
Serbian
Slovenian

Keywords

Technology Keywords:
07001001 Maquinaria agrícola / tecnología
07001009 Medicina veterinaria
07001010 Micro y nanotecnologías relacionadas con la agricultura